Needham analyst Ryan MacDonald reiterated the Buy rating on Phreesia, Inc. PHR, lowering the price target to $29 from $40.
The company's 3Q24 earnings report signaled an increased focus on returning to positive adj. EBITDA and a more balanced approach to growth and profitability.
MacDonald said he is "supportive" of this change as the push-out of the $500 million revenue run-rate target in FY25 and improved adj. EBITDA outlook removes an overhang on the stock.
However, the analyst lowered the PT to more accurately reflect a valuation multiple for a profitable business growing 20%+; the analyst sees plenty of opportunity for upside in the shares and remains a buyer of PHR.
The analyst said he is "bullish" on the opportunity for cross-selling recently acquired modules to drive subscription growth and views the LT monetization opportunity for PAM as attractive.
Looking ahead to FY25, increased focus on delivering a better balance of growth and profitability is expected to continue as Phreesia now expects FY25 adjusted EBITDA to be in the range of $10 million- $20 million, well above management's prior commentary to reach profitability in FY25 and well ahead of consensus adj. EBITDA expectations of ($17.2 million).
The analyst expects FY24 EPS of $(2.38) compared with the previous projection of $(2.48).
Price Action: PHR shares are trading higher by 20.5% to $17.78 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.